These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

659 related items for PubMed ID: 36038829

  • 1. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
    Zhang SJ, Yang Y, Sun WW, Zhang ZS, Xiao HP, Li YP, Zhang ZM, Fan L.
    BMC Infect Dis; 2022 Aug 29; 22(1):715. PubMed ID: 36038829
    [Abstract] [Full Text] [Related]

  • 2. [Study on the resistance of rifampicin-resistant Mycobacterium tuberculosis to anti-tuberculosis drugs in group A].
    Dai XW, Li CY, Wang NH, Chen SS, Tian LL, Zhao YF, Tao LY, Yang XY, Ding BC, He XX.
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov 12; 46(11):1110-1117. PubMed ID: 37914422
    [Abstract] [Full Text] [Related]

  • 3. Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition.
    Yao C, Guo H, Li Q, Zhang X, Shang Y, Li T, Wang Y, Xue Z, Wang L, Li L, Pang Y.
    Antimicrob Resist Infect Control; 2021 Aug 26; 10(1):126. PubMed ID: 34446095
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of the all-oral bedaquiline-containing regimen as treatment for pediatric multidrug/rifampicin-resistant tuberculosis: a multicenter, retrospective, cohort study.
    Sun WW, Yang M, Chen XH, Fan LC, Wu HY, Zhang SJ, Chen Y, Fan L.
    Expert Rev Anti Infect Ther; 2024 Apr 26; 22(4):219-227. PubMed ID: 37982155
    [Abstract] [Full Text] [Related]

  • 5. Safety and Effectiveness of 3 Novel All-Oral Shortened Regimens for Rifampicin- or Multidrug-Resistant Tuberculosis in Kazakhstan.
    Rashitov M, Franke MF, Trevisi L, Bekbolatova G, Shalimova J, Eshmetov G, Bektasov S, LaHood A, Arlyapova N, Osso E, Yedilbayev A, Korotych O, Ciobanu A, Skrahina A, Mitnick CD, Seung KJ, Algozhin Y, Rich ML.
    Clin Infect Dis; 2024 Oct 15; 79(4):1046-1053. PubMed ID: 38833593
    [Abstract] [Full Text] [Related]

  • 6. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
    Pai H, Ndjeka N, Mbuagbaw L, Kaniga K, Birmingham E, Mao G, Alquier L, Davis K, Bodard A, Williams A, Van Tongel M, Thoret-Bauchet F, Omar SV, Bakare N.
    BMC Infect Dis; 2022 Nov 21; 22(1):870. PubMed ID: 36414938
    [Abstract] [Full Text] [Related]

  • 7. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis in China.
    Han X, Chen X, Sha W, Zhang X, Qiu L, Wang J, Wu G, Yao L, Lv Y, Zhang X, Zhou J, Tang S, Chu N.
    Int J Tuberc Lung Dis; 2020 Aug 01; 24(8):789-794. PubMed ID: 32912383
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K, Firnhaber C, Conradie F, Ndjeka N, Sinanovic E.
    Appl Health Econ Health Policy; 2018 Feb 01; 16(1):43-54. PubMed ID: 28980217
    [Abstract] [Full Text] [Related]

  • 15. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis.
    Liu Y, Gao J, Du J, Shu W, Wang L, Wang Y, Xue Z, Li L, Xu S, Pang Y.
    Int J Infect Dis; 2021 Jan 01; 102():392-396. PubMed ID: 33130209
    [Abstract] [Full Text] [Related]

  • 16. Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial.
    Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M, Austin A, Baudin E, Bekhit M, Bektasov S, Berikova E, Bonnet M, Caboclo R, Chaudhry M, Chavan V, Cloez S, Coit J, Coutisson S, Dakenova Z, De Jong BC, Delifer C, Demaisons S, Do JM, Dos Santos Tozzi D, Ducher V, Ferlazzo G, Gouillou M, Khan U, Kunda M, Lachenal N, LaHood AN, Lecca L, Mazmanian M, McIlleron H, Moreau M, Moschioni M, Nahid P, Osso E, Oyewusi L, Panda S, Pâquet A, Thuong Huu P, Pichon L, Rich ML, Rupasinghe P, Salahuddin N, Sanchez Garavito E, Seung KJ, Velásquez GE, Vallet M, Varaine F, Yuya-Septoh FJ, Mitnick CD, Guglielmetti L.
    Trials; 2023 Nov 30; 24(1):773. PubMed ID: 38037119
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in China.
    Song Y, Shu W, Pei Y, Du J, Wu G, Wang H, Mi F, Liu F, Ma L, Xie L, Kong Z, Wu X, Liu R, Chen H, Li H, Ge Q, Nie L, Lv Z, Huang X, Li M, Jiang M, Chen X, Cai Q, Chen W, Liu Y, Miao Y, Tang Y, Chen Y, Geng S, Zhou Q, Liu Y, Pang Y, Gao M.
    BMC Med; 2024 Sep 19; 22(1):401. PubMed ID: 39300460
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.